Depression Research and Treatment
But there are some pretty important reasons, like cost savings, minimizing side effects, preventive benefits, or a combination
The GLP-1 Revolution Driving Growth Lilly dominates the obesity and diabetes market with two blockbuster drugs that are rewriting treatment paradigms: Mounjaro (Type 2 Diabetes) + Zepbound (Obesity) = $10.1B in Q3 2025 revenues (+131% YoY) Mounjaro: $6.52B (+109% YoY) Zepbound: $3.59B (+184% YoY) For context: This tirzepatide franchise just surpassed Merck's Keytruda ($8.1B in Q3) to become the world's best-selling drug
Sermorelin is, in most US clinics, no longer legally available the way it was two years ago
Once your walking workouts are no longer tiring, you dont break any sort of sweat, or your heart rate stays low, its time to up the ante
Before you inject, make sure you have: Your GLP-1 syringe Alcohol swab Sharps container Band-aid (just in case) 7